Company DNIB Unwind Inc
Equities
BINDQ
US2332421062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Zale
CTO | Chief Tech/Sci/R&D Officer | 68 | 06-10-31 |
Tom Baker
IRC | Investor Relations Contact | - | - |
Neil Bander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 16-07-23 | |
James L. Wright
PRN | Corporate Officer/Principal | 76 | 06-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 16-07-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 20,886,802 | 17,860,424 ( 85.51 %) | 0 | 85.51 % |
Company contact information
DNIB Unwind, Inc.
333 South Grand Avenue Suite 4100
90071, Los Angeles
+617-491-3400
http://bindtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BINDQ Stock
- Company DNIB Unwind Inc